Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06161675 · ClinicalTrials.gov registry record · NA

Feasibility of Delivering VergeRx at FQHCs

A NA study of Tobacco Use Cessation, sponsored by University of Virginia.

Active
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06161675: Active NA study of Tobacco Use Cessation, sponsored by University of Virginia.

NCT06161675 is a NA study of Tobacco Use Cessation that is active but no longer recruiting, run by University of Virginia. The registered enrollment target is 100 participants, below the 882-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06161675, a NA study of Tobacco Use Cessation, is active but no longer recruiting, sponsored by University of Virginia.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

Cigarette smoking in the U.S. is highest among low income and Medicaid insured adults, and unfortunately, low-income smokers are even less likely to attempt to quit, less likely to use evidence-based treatments, and thus less likely to be successful. Federally Qualified Health Centers (FQHCs), which generally provide healthcare services to low income and Medicaid insured patients, are more likely to serve individuals who use tobacco and are required to report tobacco use screening rates and their delivery of cessation interventions. Thus, FQHCs are an ideal community-partner to reach low-income smokers, particularly smokers who are not currently seeking treatment. To address this gap, the investigators developed a pharmacist-delivered smoking cessation intervention to help facilitate nicotine replacement therapy medication adherence among smokers. The proposed study aims to examine the feasibility of delivering the pharmacist-delivered smoking cessation intervention to FQHC patients who are ready to quit, and expanding the intervention for smokers not ready to quit by adding 2 pre-quit sessions focused on rate reduction. The investigators will also determine facilitators and barriers to adopting and implementing the program in FQHCs.

Primary Outcome

Measured by (a) the proportion of smokers recruited from each source (e.g., ask-advise-prescribe, posters, prescription bag advertisements) and (b) the number of smokers recruited per month.

Conditions Studied

Interventions

  • BEHAVIORAL QuitAid
  • DRUG Nicotine lozenge
  • BEHAVIORAL SmokefreeTXT
  • DRUG Nicotine Replacement Therapy Patch

Study Locations (1)

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-09-23
Est. Completion 2026-07-01
Phase NA
University of Virginia

449 total trials

What the registry record for NCT06161675 still lists

NCT06161675 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 882-participant average among 36 other Tobacco Use Cessation trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Tobacco Use Cessation appearing as the primary indexed condition, and to 4 interventions - of which QuitAid is the first listed.

NCT06161675 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT06161675 about?

NCT06161675 is a clinical study titled "Feasibility of Delivering VergeRx at FQHCs". Cigarette smoking in the U.S. is highest among low income and Medicaid insured adults, and unfortunately, low-income smokers are even less likely to attempt to quit, less likely to use evidence-based treatments, and thus less likely to be successful. Federally Qualified Health Centers (FQHCs), which...

What is the current status of trial NCT06161675?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-09-23. Estimated completion is 2026-07-01.

What conditions does trial NCT06161675 study?

This clinical trial studies the following conditions: Tobacco Use Cessation.

What interventions are being tested in trial NCT06161675?

The interventions under investigation include: QuitAid (BEHAVIORAL), Nicotine lozenge (DRUG), SmokefreeTXT (BEHAVIORAL), Nicotine Replacement Therapy Patch (DRUG).

Who is sponsoring clinical trial NCT06161675?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06161675 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06161675's enrollment target sits among peer trials

100 29th of 36 higher than 8 of 36 other Tobacco Use Cessation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Tobacco Use Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06161675, the US trial registry maintained by the National Library of Medicine. NCT06161675 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.